Before the advent of tumor molecular characterization, endometrial cancer was categorized into a less-aggressive Type I associated with diabetes, obesity, high estrogen exposure and estrogen receptor α expression, and the more-aggressive Type II, which has a higher risk of metastases and occurs more often in post-menopausal non-obese women [16]. The gene discussed is ESR1; the disease is obesity disorder.